Last reviewed · How we verify
NCT03475628: REBUILD
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
Phase 2 trial testing Daratumumab in Multiple Myeloma in 57 participants. Status unknown.
20 June 2019
Quick facts
| Lead sponsor | Hellenic Society of Hematology |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 57 |
| Start date | 21 February 2018 |
| Primary completion | 20 June 2019 |
| Estimated completion | 20 February 2020 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Daratumumab (daratumumab) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Hellenic Society of Hematology
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Abramson HN. · · 2018 · cited 42× · PMID 30544512 · DOI 10.3390/ijms19123924 -
Cell Trafficking at the Intersection of the Tumor-Immune Compartments.
Du W, Nair P, Johnston A, Wu PH, et al · · 2022 · cited 31× · PMID 35385679 · DOI 10.1146/annurev-bioeng-110320-110749 -
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.
Vallet S, Filzmoser JM, Pecherstorfer M, Podar K. · · 2018 · cited 23× · PMID 30355994 · DOI 10.3390/pharmaceutics10040202 -
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".
Terpos E, Ntanasis-Stathopoulos I, Kastritis E, Hatjiharissi E, et al · · 2022 · cited 13× · PMID 35681747 · DOI 10.3390/cancers14112768
Verify or expand the search:
- PubMed search for NCT03475628
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Daratumumab
Trials testing the same drug.
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07393282 — A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) · Phase 3 · not yet recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Hellenic Society of Hematology trials
Trials by the same sponsor.
- NCT07019545 — A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH P · Phase 2 · not yet recruiting
- NCT05573802 — A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethas · Phase 1, PHASE2 · recruiting
- NCT05581875 — A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalid · Phase 1, PHASE2 · not yet recruiting
- NCT05280275 — A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalid · Phase 1, PHASE2 · unknown
- NCT06636552 — An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Eff · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03475628 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hellenic Society of Hematology
- Last refreshed: 23 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03475628.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing